Answers are grounded in this paper and cite their sources.
Highlights the emergence of serious adverse cardiovascular events associated with tyrosine kinase inhibitors ponatinib and nilotinib in the treatment of chronic myeloid leukemia.
The story of impressive evolution in treatment for chronic myeloid leukemia has taken an unexpected turn, as serious adverse cardiovascular events have occurred in patients treated with the tyrosine kinase inhibitors ponatinib and nilotinib.
No takes yet. Share an insight, caveat, or question.
Groarke et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: